Literature DB >> 2513112

Interferon-gamma (IFN-gamma) and interleukin-2 in the generation of lymphokine-activated killer cell cytotoxicity--IFN-gamma-induced suppressive activity.

M Toledano1, C Mathiot, J Michon, G Andreu, D Lando, M Brandely, W H Fridman.   

Abstract

Incubation of human lymphocytes with recombinant interleukin-2 (rIL-2) results in the generation of lymphokine-activated killer (LAK) cells capable of lysing a wide variety of tumor cells. The present study was undertaken to examine the effect of recombinant gamma interferon (rIFN-gamma) on LAK cell cytotoxicity generated from different peripheral blood mononuclear cell (PBMC) subpopulations. When unseparated PBMC were stimulated by rIL-2 and rIFN-gamma, the latter induced a transient enhancement after 2 days followed by a suppression of LAK cell cytotoxicity at day 6. Enhancement of LAK cell cytotoxicity was moderate and inconstant, whereas the inhibition was strong and observed with all the donors tested. This suppression was not associated with a decrease in the [3H]thymidine uptake. PBMC depleted of adherent cells were more sensitive to the stimulation by rIL-2 and the induced cytotoxicity was not modified by rIFN-gamma. Monocyte-enriched plastic-adherent cells, when incubated with rIL-2 and rIFN-gamma, became cytotoxic after 2-3 days of culture and inhibited LAK cell activity after 5-6 days. Collectively, our results suggest that rIFN-gamma affects LAK cell cytotoxicity through the activation of plastic-adherent, monocyte-rich, cells which modulate natural killer cells, first in a positive, then in a negative way.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2513112     DOI: 10.1007/bf01665031

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  26 in total

1.  Qualitative differences in effects of recombinant alpha-, beta- and gamma-interferons on human peripheral blood leukocytes in vitro.

Authors:  C Billard; D Ferbus; J P Kolb; F Rosa; J Y Perrot; G Merlin; P Janiaud; N Raynaud; M N Thang; M Fellous
Journal:  Ann Inst Pasteur Immunol (1985)       Date:  1986 May-Jun

2.  Characterization and modulation of human lymphokine (interleukin 2) activated killer cell induction.

Authors:  M Hoyer; T Meineke; W Lewis; B Zwilling; J Rinehart
Journal:  Cancer Res       Date:  1986-06       Impact factor: 12.701

3.  Recombinant interferon-gamma induces interleukin 2 receptors on human peripheral blood monocytes.

Authors:  W Holter; R Grunow; H Stockinger; W Knapp
Journal:  J Immunol       Date:  1986-03-15       Impact factor: 5.422

Review 4.  Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes.

Authors:  S A Rosenberg; M T Lotze
Journal:  Annu Rev Immunol       Date:  1986       Impact factor: 28.527

5.  Recombinant interleukin-2 directly augments the cytotoxicity of human monocytes.

Authors:  M Malkovský; B Loveland; M North; G L Asherson; L Gao; P Ward; W Fiers
Journal:  Nature       Date:  1987 Jan 15-21       Impact factor: 49.962

6.  Natural killer (NK) cells as a responder to interleukin 2 (IL 2). II. IL 2-induced interferon gamma production.

Authors:  K Handa; R Suzuki; H Matsui; Y Shimizu; K Kumagai
Journal:  J Immunol       Date:  1983-02       Impact factor: 5.422

7.  Effects of human alveolar macrophages on the induction of lymphokine (IL 2)-activated killer cells.

Authors:  S Sone; T Utsugi; A Nii; T Ogura
Journal:  J Immunol       Date:  1987-07-01       Impact factor: 5.422

8.  Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer.

Authors:  W H West; K W Tauer; J R Yannelli; G D Marshall; D W Orr; G B Thurman; R K Oldham
Journal:  N Engl J Med       Date:  1987-04-09       Impact factor: 91.245

9.  Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity.

Authors:  L B Owen-Schaub; J U Gutterman; E A Grimm
Journal:  Cancer Res       Date:  1988-02-15       Impact factor: 12.701

10.  Natural killer-mediated lysis of normal and malignant target cells, and its regulation by monocytes.

Authors:  K Oshimi; Y Oshimi; M Satake; H Mizoguchi
Journal:  J Exp Med       Date:  1985-08-01       Impact factor: 14.307

View more
  10 in total

1.  Phase I trial with recombinant interleukin-2 (rIL-2): immune activation by rIL-2 alone or following pretreatment with recombinant interferon-gamma.

Authors:  F Farace; C Mathiot; M Brandely; T Tursz; T Dorval; P Pouillart; F Triebel; T Hercend; W H Fridman
Journal:  Clin Exp Immunol       Date:  1990-11       Impact factor: 4.330

2.  Evidence that interleukin-4 suppression of lymphokine-activated killer cell induction is mediated through monocytes.

Authors:  B Brooks; H Parry; J Lawry; R Rees
Journal:  Immunology       Date:  1992-02       Impact factor: 7.397

3.  A Viscum album oligosaccharide activating human natural cytotoxicity is an interferon gamma inducer.

Authors:  E A Mueller; F A Anderer
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

4.  Suppression of lymphokine-activated killer (LAK) cell induction mediated by interleukin-4 and transforming growth factor-beta 1: effect of addition of exogenous tumour necrosis factor-alpha and interferon-gamma, and measurement of their endogenous production.

Authors:  B Brooks; K Chapman; J Lawry; A Meager; R C Rees
Journal:  Clin Exp Immunol       Date:  1990-12       Impact factor: 4.330

Review 5.  Human nonspecific suppressive lymphokines.

Authors:  M T Halpern
Journal:  J Clin Immunol       Date:  1991-01       Impact factor: 8.317

6.  Effect of interleukin (IL)-12 and IL-15 on activated natural killer (ANK) and antibody-dependent cellular cytotoxicity (ADCC) in HIV infection.

Authors:  S J Lin; R L Roberts; B J Ank; Q H Nguyen; E K Thomas; E R Stiehm
Journal:  J Clin Immunol       Date:  1998-09       Impact factor: 8.317

7.  Increased expression of perforin and granzyme B genes in patients with metastatic melanoma treated with recombinant interleukin-2.

Authors:  M B Leger-Ravet; C Mathiot; A Portier; M Brandely; P Galanaud; W H Fridman; D Emilie
Journal:  Cancer Immunol Immunother       Date:  1994-07       Impact factor: 6.968

8.  Induction of bacillus-Calmette-Guérin-activated killer cells from human peripheral blood mononuclear cells against human bladder carcinoma cell lines in vitro.

Authors:  A Thanhäuser; A Böhle; H D Flad; M Ernst; T Mattern; A J Ulmer
Journal:  Cancer Immunol Immunother       Date:  1993-07       Impact factor: 6.968

9.  Decrease in lymphokine-activated killer sensitivity of a human renal-cell carcinoma cell line after cytokine treatment.

Authors:  M Yanase; T Tsukamoto; Y Kumamoto; K Kato; Y Hashimoto
Journal:  Cancer Immunol Immunother       Date:  1994-07       Impact factor: 6.968

10.  Immunomodulation in patients receiving intravenous Bryostatin 1 in a phase I clinical study: comparison with effects of Bryostatin 1 on lymphocyte function in vitro.

Authors:  C Scheid; J Prendiville; G Jayson; D Crowther; B Fox; G R Pettit; P L Stern
Journal:  Cancer Immunol Immunother       Date:  1994-10       Impact factor: 6.968

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.